Boston Scientific (NYSE:BSX) Price Target Raised to $130.00

Boston Scientific (NYSE:BSX) had its price objective increased by Truist Financial from $129.00 to $130.00 in a report issued on Thursday, Marketbeat Ratings reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Several other analysts also recently commented on BSX. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Morgan Stanley upped their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday. Robert W. Baird upped their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Finally, Raymond James Financial increased their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Trading Down 1.3%

Shares of Boston Scientific stock opened at $101.08 on Thursday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 12-month low of $80.64 and a 12-month high of $109.50. The firm has a market capitalization of $149.78 billion, a price-to-earnings ratio of 54.06, a PEG ratio of 2.34 and a beta of 0.61. The firm’s 50 day simple moving average is $101.14 and its two-hundred day simple moving average is $102.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the business posted $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Analysts predict that Boston Scientific will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock valued at $17,548,337 over the last ninety days. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds have recently modified their holdings of BSX. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after buying an additional 3,745 shares during the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider’s stock valued at $3,987,000 after buying an additional 6,264 shares during the last quarter. Legacy Advisors LLC raised its position in shares of Boston Scientific by 12.9% in the first quarter. Legacy Advisors LLC now owns 3,905 shares of the medical equipment provider’s stock valued at $394,000 after buying an additional 446 shares during the last quarter. Finally, Spire Wealth Management raised its position in shares of Boston Scientific by 15.9% in the first quarter. Spire Wealth Management now owns 10,630 shares of the medical equipment provider’s stock valued at $1,072,000 after buying an additional 1,456 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.